Tegoprazan‐Based Triple Therapy for Helicobacter pylori Eradication: A Phase III Multicenter Randomized Clinical Trial

医学 随机对照试验 内科学 临床试验 相(物质) 临床研究阶段 外科 多中心试验 梅德林 多中心研究
作者
Jae Yong Park,SJ Hong,IJ Choi,Gwang Ho Baik,Sun Moon Kim,Jong‐Jae Park,Seong Woo Jeon,Kyung‐Oh Kim,Sang Kil Lee,Hwoon‐Yong Jung,Jung‐Hwan Oh,Chan Hyuk Park,Sang WooK Kim,Ki‐Nam Shim,Sam Ryong Jee,Hee Seok Moon,Jeong Seop Moon,Cheol Woong Choi,Wan‐Sik Lee,Jae Gyu Kim
出处
期刊:Helicobacter [Wiley]
卷期号:31 (1): e70106-e70106 被引量:13
标识
DOI:10.1111/hel.70106
摘要

BACKGROUND: Tegoprazan, a potassium-competitive acid blocker, offers potent and sustained acid inhibition and potentially improves eradication efficacy. AIM: This study aimed to evaluate the efficacy and safety of tegoprazan-based triple therapy with two dosing regimens compared with that of lansoprazole-based therapy for first-line Helicobacter pylori eradication. METHODS: This randomized, double-blind, active-controlled, multicenter trial was conducted at 19 referral hospitals in South Korea (February 2023-April 2024). Treatment-naïve adults with H. pylori infection were randomized 1:1:1 to receive 14-day triple therapy with tegoprazan, 50 mg (TAC1), tegoprazan, 100 mg (TAC2), or lansoprazole, 30 mg (LAC), each combined with amoxicillin 1000 mg and clarithromycin 500 mg, administered twice daily. The primary endpoint was H. pylori eradication rate in the modified intention-to-treat (mITT) population, with a non-inferiority margin of -10%. Secondary endpoints included subgroup analyses based on clarithromycin resistance and safety assessments. RESULTS: Of the 564 screened patients, 382 were randomized. In the mITT analysis (mean age, 54.9 years; 54.3% male), eradication rates were 86.0%, 85.5%, and 78.7% for TAC1, TAC2, and LAC, respectively. Both tegoprazan-based regimens met the non-inferiority criteria. Among clarithromycin-resistant infections, the eradication rates were higher for TAC1 (47.8%) and TAC2 (50.0%) than for LAC (35.5%), although the difference was not statistically significant. Safety profiles were comparable across the groups, with no serious drug-related adverse events. CONCLUSION: Tegoprazan-based triple therapies, at 50- and 100-mg doses, were non-inferior to lansoprazole-based therapy and were well tolerated. Our findings indicated that tegoprazan-based triple therapy is a viable first-line option for H. pylori eradication. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT05933031.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
音韵公主完成签到 ,获得积分10
1秒前
小陆完成签到,获得积分10
2秒前
挚友发布了新的文献求助10
2秒前
2秒前
领导范儿的应助被巫雍采纳,获得10
2秒前
桃桃甜筒发布了新的文献求助10
2秒前
KK完成签到,获得积分10
2秒前
caoshanyu完成签到,获得积分20
3秒前
3秒前
海绵发布了新的文献求助10
3秒前
3秒前
jjjj完成签到,获得积分10
3秒前
3秒前
隐形曼青的应助被瘦瘦青文采纳,获得10
3秒前
null的应助被TMEDA采纳,获得10
3秒前
3秒前
Jasper的应助被timi2026采纳,获得10
3秒前
zy完成签到,获得积分10
3秒前
粟禾发布了新的文献求助10
4秒前
玥洋完成签到 ,获得积分10
4秒前
ZYC007发布了新的文献求助10
4秒前
hua发布了新的文献求助10
4秒前
平淡语薇发布了新的文献求助10
4秒前
4秒前
Austin发布了新的文献求助10
4秒前
4秒前
kaka完成签到,获得积分10
5秒前
5秒前
5秒前
备注发布了新的文献求助10
5秒前
5秒前
5秒前
情怀的应助被六金采纳,获得10
5秒前
芋泥泥泥完成签到,获得积分10
5秒前
酷波er的应助被楠木木采纳,获得10
6秒前
心灵美的清完成签到,获得积分10
6秒前
YHY完成签到,获得积分10
6秒前
高芷完成签到 ,获得积分10
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175943
求助须知:如何正确求助?哪些是违规求助? 9567501
关于积分的说明 21793186
捐赠科研通 7770490
什么是DOI,文献DOI怎么找? 3431935
关于科研通互助平台的介绍 2556294
邀请新用户注册赠送积分活动 2477485